1016 related articles for article (PubMed ID: 34675919)
21. Oncolytic herpes simplex virus therapy for malignant glioma: current approaches to successful clinical application.
Hua L; Wakimoto H
Expert Opin Biol Ther; 2019 Aug; 19(8):845-854. PubMed ID: 31046478
[TBL] [Abstract][Full Text] [Related]
22. Oncolytic virotherapy as promising immunotherapy against cancer: mechanisms of resistance to oncolytic viruses.
Goradel NH; Alizadeh A; Hosseinzadeh S; Taghipour M; Ghesmati Z; Arashkia A; Negahdari B
Future Oncol; 2022 Jan; 18(2):245-259. PubMed ID: 34821517
[TBL] [Abstract][Full Text] [Related]
23. Engineering strategies to enhance oncolytic viruses in cancer immunotherapy.
Tian Y; Xie D; Yang L
Signal Transduct Target Ther; 2022 Apr; 7(1):117. PubMed ID: 35387984
[TBL] [Abstract][Full Text] [Related]
24. Oncolytic Viruses: Therapeutics With an Identity Crisis.
Breitbach CJ; Lichty BD; Bell JC
EBioMedicine; 2016 Jul; 9():31-36. PubMed ID: 27407036
[TBL] [Abstract][Full Text] [Related]
25. Oncolytic virus immunotherapy: future prospects for oncology.
Raja J; Ludwig JM; Gettinger SN; Schalper KA; Kim HS
J Immunother Cancer; 2018 Dec; 6(1):140. PubMed ID: 30514385
[TBL] [Abstract][Full Text] [Related]
26. Introduction to Oncolytic Virotherapy.
Engeland CE; Bell JC
Methods Mol Biol; 2020; 2058():1-6. PubMed ID: 31486028
[TBL] [Abstract][Full Text] [Related]
27. Clinical CAR-T Cell and Oncolytic Virotherapy for Cancer Treatment.
Watanabe N; McKenna MK; Rosewell Shaw A; Suzuki M
Mol Ther; 2021 Feb; 29(2):505-520. PubMed ID: 33130314
[TBL] [Abstract][Full Text] [Related]
28. Novel Oncolytic Herpes Simplex Virus 1 VC2 Promotes Long-Lasting, Systemic Anti-melanoma Tumor Immune Responses and Increased Survival in an Immunocompetent B16F10-Derived Mouse Melanoma Model.
Uche IK; Fowlkes N; Vu L; Watanabe T; Carossino M; Nabi R; Del Piero F; Rudd JS; Kousoulas KG; Rider PJF
J Virol; 2021 Jan; 95(3):. PubMed ID: 33177208
[TBL] [Abstract][Full Text] [Related]
29. Oncolytic virotherapy evolved into the fourth generation as tumor immunotherapy.
Wang X; Shen Y; Wan X; Hu X; Cai WQ; Wu Z; Xin Q; Liu X; Gui J; Xin HY; Xin HW
J Transl Med; 2023 Jul; 21(1):500. PubMed ID: 37491263
[TBL] [Abstract][Full Text] [Related]
30. The need for paradigm shift: prognostic significance and implications of standard therapy-related systemic immunosuppression in glioblastoma for immunotherapy and oncolytic virotherapy.
Stepanenko AA; Sosnovtseva AO; Valikhov MP; Chernysheva AA; Abramova OV; Naumenko VA; Chekhonin VP
Front Immunol; 2024; 15():1326757. PubMed ID: 38390330
[TBL] [Abstract][Full Text] [Related]
31. Implications of immune cells in oncolytic herpes simplex virotherapy for glioma.
Otani Y; Yoo JY; Shimizu T; Kurozumi K; Date I; Kaur B
Brain Tumor Pathol; 2022 Apr; 39(2):57-64. PubMed ID: 35384530
[TBL] [Abstract][Full Text] [Related]
32. Oncolytic Virotherapy Treatment of Breast Cancer: Barriers and Recent Advances.
Kwan A; Winder N; Muthana M
Viruses; 2021 Jun; 13(6):. PubMed ID: 34208264
[TBL] [Abstract][Full Text] [Related]
33. Oncolytic H-1 Parvovirus Shows Safety and Signs of Immunogenic Activity in a First Phase I/IIa Glioblastoma Trial.
Geletneky K; Hajda J; Angelova AL; Leuchs B; Capper D; Bartsch AJ; Neumann JO; Schöning T; Hüsing J; Beelte B; Kiprianova I; Roscher M; Bhat R; von Deimling A; Brück W; Just A; Frehtman V; Löbhard S; Terletskaia-Ladwig E; Fry J; Jochims K; Daniel V; Krebs O; Dahm M; Huber B; Unterberg A; Rommelaere J
Mol Ther; 2017 Dec; 25(12):2620-2634. PubMed ID: 28967558
[TBL] [Abstract][Full Text] [Related]
34. IL-36γ-armed oncolytic virus exerts superior efficacy through induction of potent adaptive antitumor immunity.
Yang M; Giehl E; Feng C; Feist M; Chen H; Dai E; Liu Z; Ma C; Ravindranathan R; Bartlett DL; Lu B; Guo ZS
Cancer Immunol Immunother; 2021 Sep; 70(9):2467-2481. PubMed ID: 33538860
[TBL] [Abstract][Full Text] [Related]
35. Multi-modal Potentiation of Oncolytic Virotherapy by Vanadium Compounds.
Selman M; Rousso C; Bergeron A; Son HH; Krishnan R; El-Sayes NA; Varette O; Chen A; Le Boeuf F; Tzelepis F; Bell JC; Crans DC; Diallo JS
Mol Ther; 2018 Jan; 26(1):56-69. PubMed ID: 29175158
[TBL] [Abstract][Full Text] [Related]
36. Oncolytic Virotherapy in Glioma Tumors.
Rius-Rocabert S; García-Romero N; García A; Ayuso-Sacido A; Nistal-Villan E
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33066689
[TBL] [Abstract][Full Text] [Related]
37. Oncolytic viruses and their application to cancer immunotherapy.
Chiocca EA; Rabkin SD
Cancer Immunol Res; 2014 Apr; 2(4):295-300. PubMed ID: 24764576
[TBL] [Abstract][Full Text] [Related]
38. Oncolytic viruses combined with immune checkpoint therapy for colorectal cancer is a promising treatment option.
Ren Y; Miao JM; Wang YY; Fan Z; Kong XB; Yang L; Cheng G
Front Immunol; 2022; 13():961796. PubMed ID: 35911673
[TBL] [Abstract][Full Text] [Related]
39. Oncolytic viruses and immunity.
Chaurasiya S; Chen NG; Fong Y
Curr Opin Immunol; 2018 Apr; 51():83-90. PubMed ID: 29550660
[TBL] [Abstract][Full Text] [Related]
40. Synergistic interaction between oncolytic viruses augments tumor killing.
Le Boeuf F; Diallo JS; McCart JA; Thorne S; Falls T; Stanford M; Kanji F; Auer R; Brown CW; Lichty BD; Parato K; Atkins H; Kirn D; Bell JC
Mol Ther; 2010 May; 18(5):888-95. PubMed ID: 20234341
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
